Paclitaxel for Gastric Cancer: 22 Real Stories

22 stories match gastric cancer and paclitaxel. 17 of them mention targeted therapy.

Cancer Stories

Derek, who was diagnosed with Stage IV Gastric AdenocarcinomaGastric Cancer

Stage IV Gastric Adenocarcinoma: Derek's Survivor Story

Patient Info: Derek Cooney, Male, 40s | Stage IV

Metastatic Site: peritoneum

At his first follow-up in June, scans showed no evidence of disease, and he later completed his pain-management fellowship.

MD Anderson
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Gastric AdenocarcinomaGastric Cancer

Gastric cancer treatment during hemodialysis after liver recurrence

Patient Info: Anonymized, Male, 60s | Stage IV

Biomarkers: HER2-negative

Metastatic Site: liver|peritoneum

The cancer progressed in the peritoneum despite treatment, and systemic therapy was stopped in August 2024 before transfer to hospice in October 2024.

PubMed Central
OutcomeSetback / Progression
A patient, who was diagnosed with Stage IV Gastric AdenocarcinomaGastric Cancer

Stage IV gastric cancer with benign breast hemangioma during ramucirumab therapy

Patient Info: Anonymized, Female, Under 40 | Stage IV

Biomarkers: Gastric cancer: HER2 negative, PD-L1 TPS >=5%

Metastatic Site: peritoneum; preaortic lymph nodes; omentum

After initial response to FOLFOX/nivolumab and temporary benefit from paclitaxel/ramucirumab and FOLFIRI, the gastric cancer progressed to massive ascites. Trifluridine/tipiracil was attempted, but she died from rapid disease progression.

PubMed Central
OutcomeIn Memory
A patient, who was diagnosed with Stage IV Gastric CancerGastric Cancer

ALK-Fusion Gastric Cancer Responds to Alectinib Before Progression

Patient Info: Anonymized, female, 50s | Stage IV

Biomarkers: DCTN1–ALK fusion; ATM p.E1724*; CDK6 amplification; HER2 negative; mismatch-repair proteins intact; later KRAS amplification

Metastatic Site: bone

Alectinib produced a partial response for about 11.5 months, but the cancer later progressed systemically and she died from uncontrollable gastrointestinal bleeding.

PubMed Central
OutcomeIn Memory
A patient, who was diagnosed with Stage IV Gastric AdenocarcinomaGastric Cancer

HER2-positive metastatic gastric cancer responding to trastuzumab deruxtecan rechallenge

Patient Info: Anonymized, male, 60s | Stage IV

Biomarkers: HER2-positive

Metastatic Site: liver

After trastuzumab deruxtecan was restarted, his symptoms improved after the first cycle and imaging showed tumor shrinkage after 3 cycles. He was still receiving treatment without progression at the latest follow-up.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Stage IV Gastric CancerGastric Cancer

Kidney Injury During Nivolumab Treatment for Stage IV Gastric Cancer

Patient Info: Anonymized, Male, 60s | Stage IV

Kidney function and proteinuria improved after nivolumab was stopped, but the gastric cancer progressed. Restarted nivolumab was ineffective, and treatment was changed to irinotecan.

PubMed Central
OutcomeSetback / Progression
A patient, who was diagnosed with Gastric AdenocarcinomaGastric Cancer

Kidney Disease During Treatment for Metastatic Gastric Cancer

Patient Info: Anonymized, Male, 70+ | Stage Metastatic/Advanced

Metastatic Site: liver

His condition worsened with nephrotic syndrome, malnutrition, treatment side effects, and progressing metastases. He died 5 months after the kidney biopsy following a fatal cerebral bleed.

PubMed Central
OutcomeIn Memory
A patient, who was diagnosed with Stage IV Gastric AdenocarcinomaGastric Cancer

Ramucirumab and paclitaxel for metastatic gastric cancer in a patient receiving hemodialysis

Patient Info: Anonymized, male, 60s | Stage IV

Biomarkers: HER2-negative

Metastatic Site: liver, distant lymph nodes

After about 16 months of disease control on paclitaxel plus ramucirumab, multiple liver metastases and distant lymph nodes progressed. Third-line irinotecan was stopped after severe toxicity, and supportive care followed.

PubMed Central
OutcomeSetback / Progression
A patient, who was diagnosed with Stage IV Gastric AdenocarcinomaGastric Cancer

Sjögren syndrome during nivolumab treatment for HER2-positive metastatic gastric cancer

Patient Info: Anonymized, male, 60s | Stage IV

Biomarkers: HER2-positive

Metastatic Site: liver, lungs, adrenal gland

One year after nivolumab was stopped, the shrinkage of lung metastases was maintained and the adrenal metastasis remained unchanged, although severe dry-mouth symptoms from treatment-related Sjögren syndrome persisted.

PubMed Central
OutcomeStable Disease
A patient, who was diagnosed with Stage IV Gastric CancerGastric Cancer

Graves disease during nivolumab treatment for HER2-positive metastatic gastric cancer

Patient Info: Anonymized, male, 60s | Stage IV

Biomarkers: HER2-positive

Metastatic Site: liver, brain

After progression through several treatment lines and development of brain metastasis, he died 4 months after evaluation for nivolumab-associated Graves disease, more than 1.5 years after his Stage IV gastric-cancer diagnosis.

PubMed Central
OutcomeIn Memory
A patient, who was diagnosed with Stage IV Gastric AdenocarcinomaGastric Cancer

Clival skull-base metastasis during treatment for Stage IV gastric cancer

Patient Info: Anonymized, male, 70+ | Stage IV

Biomarkers: HER2-negative

Metastatic Site: peritoneum, cervical lymph nodes, pelvic bone, lungs,…

At publication he was alive on fourth-line treatment, with no disease progression for 6 months after the clival metastasis was treated and with sustained improvement in his cranial-nerve symptoms.

PubMed Central
OutcomeStable Disease
A patient, who was diagnosed with Stage IV Gastric Squamous Cell CarcinomaGastric Cancer

Primary gastric squamous cell carcinoma with early chest metastases

Patient Info: Anonymized, male, 60s | Stage IV

Biomarkers: HER2-negative

Metastatic Site: lungs, distant lymph nodes

Twelve months after chemotherapy began, the metastatic chest lesions had not progressed and showed minor regression.

PubMed Central
OutcomeStable Disease